Aduhelm Looks Set For Rejection In Europe For Alzheimer's

Adds To US Woes

The EMA’s likely rejection is no surprise for Biogen and Eisai, but adds to problems in the same week as Biogen’s R&D leader announced his departure.

Biogen_Switzerland
Hopes of an EU launch in 2022 are now diminishing, with EU regulators expected to demand a further trial to demonstrate Aduhelm' s efficacy. • Source: Alamy

The European Medicines Agency’s expert committee looks set to reject Biogen and Eisai’s Alzheimer’s treatment Aduhelm (aducanumab), adding further bad news to the drug’s troubled and controversial US launch.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

 
• By 

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By 

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By 

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

More from Scrip

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By 

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.